Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants Life Science Investing
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million Life Science Investing
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Life Science Investing
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China Life Science Investing
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth Life Science Investing
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update Life Science Investing
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Life Science Investing
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer Life Science Investing
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Life Science Investing
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates Life Science Investing
